Ex-situ liver machine perfusion: the impact of fresh frozen plasma.
The primary aim of this single-center, Phase-I exploratory study was to investigate the safety, feasibility, and impact on intrahepatic hemodynamics of a fresh frozen plasma (FFP)-based perfusate in ex situ liver normothermic machine perfusion (NMP) preservation. Using an institutionally developed perfusion device 21 livers (13 donors after brain death, 8 donors after cardiac death) were perfused for 3hr21min to 7hr52min and successfully transplanted. Outcomes were compared in a 1:4 ratio to historic controls matched according to donor and recipient characteristics and preservation time. Perfused livers presented a very low resistance state with high flow during ex situ perfusion (arterial and portal flows 340±150 and 890±70 ml/min/kg liver respectively). This hemodynamic state was maintained even after reperfusion as demonstrated by higher arterial flow observed in the NMP group compared to controls (220±120 vs. 160±80 ml/min/kg liver, P=.03). The EAD rate, peak alanine aminotransaminase (ALT) and aspartate aminotransaminase (AST) levels within 7 days after transplantation were lower in the NMP group compared to the controls (EAD 19% vs. 46%, P =.02; peak ALT 363±318 vs. 1021±999 U/L, P = 0.001; peak AST 1357±1492 vs. 2615±2541 U/L, P =.001 of the NMP and control groups respectively). No patient developed ischemic type biliary stricture. All but one patient are alive and well at a follow up of 12-35 months. No device related adverse events were recorded. In conclusion, with this study we showed that ex situ NMP of human livers can be performed safely and effectively using a non-commercial device and an FFP-based preservation solution. Future study will have to investigate further the impact of an FFP-based perfusion solution on liver hemodynamics during ex situ normothermic machine preservation.